Wedbush Reiterates Outperform on Kura Oncology, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Kura Oncology (NASDAQ:KURA) and maintained a price target of $37.
August 09, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Kura Oncology and maintained a price target of $37.
The reiteration of an Outperform rating and a maintained price target of $37 by a reputable analyst can boost investor confidence in Kura Oncology, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100